戴士杰

科研成果：

[1]国自然青年科学基金项目（C类），82204217，具有抗体募集功能的FGFR1拮抗肽的化学酶法合成、抗肿瘤活性及其作用机制研究，2023-01-01 至 2025-12-31，30万元，在研，主持；

[2] 温州医科大学登峰学科（药学）学科“细胞生长因子与疾病” 二级学科方向学术骨干，基于AI 技术和药物设计新策略，靶向FGFR1非天然肽配体药物的设计、合成及活性研究，2025-01-01 至 2027-12-31，30万元，在研，主持；

2.所获成果（包括科研成果奖、专利、专著等）

[1] 戴士杰,刘海雁,宋佳,蔡跃飘,李晓会,陈惠,丁圣洁,田子玉. 具有抗体募集功能的 FGFR1 拮抗肽衍生物及其合成和抗肿瘤应用. 专利号：ZL 202410048195.0 (实施审查).

[2] 吴志猛，周志昉，李晨，戴士杰，刘少中. 带有羟胺基的艾塞那肽类似物及其应用.专利号：ZL 201810613152.7 (已授权).

3.发表论文（具有代表性的5篇）

[1] Li Xiaohui，Liu Haiyan, Ding Shengjie, Tian Ziyu, Song Jia, Zhong Huayu, Fu Luwei, Cai Xiaojun, Huang Fengyu, Wang Kun, Dong Lilong, Zhao Weixin*, Cai Yuepiao*, Dai Shijie*. Chemoenzymatic Synthesis of DNP-Functionalized FGFR1-Binding Peptides as Novel Peptidomimetic Immunotherapeutics for Treating Lung Cancer [J]. Journal of Medicinal Chemistry, 2024.

[2] Zhao Weixin，Chen Mengyu，Yu Xialin，Zhong Huayu，Hao Shikang，Liu Shuangyu，Tian Ziyu，Dong Lilong，Dai Shijie*，Liu Haiyan*，Hao Han*. 4-Methylesculetin attenuates inflammatory pain via inhibition of Sp1-TRPV1 and inflammation related signaling pathways[J]. International Immunopharmacology, 2025, 152(16): 114379-114392.

[3] Dai Shijie, Hong Haofei, Zhou Kun, Zhao Kai, Xie Yuntian, Li Chen, Shi Jie, Zhou Zhifang, Nie Lei*, Wu Zhimeng*. Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibody for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity [J]. Journal of Medicinal Chemistry, 2021.

[4] Dai Shijie, Liu Shaozhong, Li Chen, Zhou Zhifang, Wu Zhimeng*. Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment[J]. Carbohydrate Polymers, 2020:116864.

[5] Huang Fengyu，Shi Xueqin，Hu Meng，Yan Hang，Li Xiaohui，Ding Yujie，Zheng Xinxin，Cai Xiaojun，Dai Shijie; Xia Qinqin，Cai Yuepiao. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway[J]. European Journal of Pharmacology, 2024, 970: 176493-176503